Kaplan-Meier plots of PFS in 95 patients with HHV8⁺ MCD after rituximab-based therapy. (A) Whole cohort (n = 95); 5-year PFS, 54.4% (95% CI, 40.8-66.0); (B) 5-year PFS was lower in patients who were HIV^– (red line, n = 25): 25.7% (95% CI, 5.2-63.6) than in those who were HIV⁺ (dashed line, n = 70): 61.6% (95% CI, 46.2-73.7); log-rank test; P = .02.